SLC5A2 and diabetic kidney disease: For those in the SGLT2 inhibitor cohort, those in the highest quartile of OOP costs were similarly older (mean [SD] age, 73.3 [9.0] years vs 69.9 [10.9] years), more likely to be male (11 932 [59.5%] vs 10 405 [51.4%]), more likely to be White (13 997 [69.8%] vs 10 943 [54.1%]), and had a higher proportion with diabetic nephropathy (4370 [21.8%] vs 3783 [18.7%]), all when compared against those in the lowest quartile of OOP costs (Table 1).